open access

Vol 57, No 6 (2006)
Original papers
Published online: 2006-11-29
Submitted: 2013-02-15
Get Citation

Predicting a relapse of Graves’ hyperthyroidism in adults during the early phase of treatment with anti-thyroid drugs

Marta Jonas, Urszula Ambroziak, Tomasz Bednarczuk, Janusz Nauman
Endokrynologia Polska 2006;57(6):596-604.

open access

Vol 57, No 6 (2006)
Original papers
Published online: 2006-11-29
Submitted: 2013-02-15

Abstract

Introduction: The long-term effectiveness of anti-thyroid drugs (ATD) in the treatment of Graves’ hyperthyroidism (GH) is still unsatisfactory and difficult to predict. The aim of this study was to evaluate the usefulness of a determination of serum level of thyrotropin-binding inhibiting immunoglobulins (second generation TBII assay) in predicting the possibility of relapse in the early phase of pharmacological treatment.
Material and methods: We investigated 37 patients within the 20-60 age range with the first occurrence of GH. All patients were treated with thiamazole for 12 months. Clinical assessment, ultrasound estimation of thyroid volume and determination of serum thyrotropin, free thyroxine, free triiodothyronine, thyroid autoantibodies and TBII levels were carried out at the onset and after 1, 3, 6, 9 and 12 months of ATD treatment.
Results: The mean follow-up period after ATD withdrawal was 27.24 ± 5.81 months. Of 37 patients 12 (32%) had a relapse of hyperthyroidism (mean time 8.17 ± 6.91 months after drug withdrawal). The difference in TBII levels between the relapse and the remission group was found to be significant after the first month of therapy until the end of ATD treatment. We observed that patients with TBII above 14 IU/L after 3 months and above 8 IU/L after 6 months of therapy relapsed more frequently than patients with lower levels (sensitivity 50% and specificity 92 and 96%, respectively).
Conclusions: The study confirmed that TBII estimation in the early phase of ATD could be useful in the proper planning of GH therapy and early qualification to more radical treatment (radioiodine or surgery).

Abstract

Introduction: The long-term effectiveness of anti-thyroid drugs (ATD) in the treatment of Graves’ hyperthyroidism (GH) is still unsatisfactory and difficult to predict. The aim of this study was to evaluate the usefulness of a determination of serum level of thyrotropin-binding inhibiting immunoglobulins (second generation TBII assay) in predicting the possibility of relapse in the early phase of pharmacological treatment.
Material and methods: We investigated 37 patients within the 20-60 age range with the first occurrence of GH. All patients were treated with thiamazole for 12 months. Clinical assessment, ultrasound estimation of thyroid volume and determination of serum thyrotropin, free thyroxine, free triiodothyronine, thyroid autoantibodies and TBII levels were carried out at the onset and after 1, 3, 6, 9 and 12 months of ATD treatment.
Results: The mean follow-up period after ATD withdrawal was 27.24 ± 5.81 months. Of 37 patients 12 (32%) had a relapse of hyperthyroidism (mean time 8.17 ± 6.91 months after drug withdrawal). The difference in TBII levels between the relapse and the remission group was found to be significant after the first month of therapy until the end of ATD treatment. We observed that patients with TBII above 14 IU/L after 3 months and above 8 IU/L after 6 months of therapy relapsed more frequently than patients with lower levels (sensitivity 50% and specificity 92 and 96%, respectively).
Conclusions: The study confirmed that TBII estimation in the early phase of ATD could be useful in the proper planning of GH therapy and early qualification to more radical treatment (radioiodine or surgery).
Get Citation

Keywords

Graves’ disease; hyperthyroidism; autoantibodies; TSH receptor; TBII

About this article
Title

Predicting a relapse of Graves’ hyperthyroidism in adults during the early phase of treatment with anti-thyroid drugs

Journal

Endokrynologia Polska

Issue

Vol 57, No 6 (2006)

Pages

596-604

Published online

2006-11-29

Bibliographic record

Endokrynologia Polska 2006;57(6):596-604.

Keywords

Graves’ disease
hyperthyroidism
autoantibodies
TSH receptor
TBII

Authors

Marta Jonas
Urszula Ambroziak
Tomasz Bednarczuk
Janusz Nauman

Important: This website uses cookies.tanya dokter More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl